Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden

BackgroundElderly persons with a dementia diagnosis often suffer from different neuropsychiatric symptoms (NPS) such as delusions, hallucinations, depression, anxiety, irritability and agitation. Currently, the medical treatment for NPS consists mostly of psychotropic medication such as hypnotics/sedatives, anxiolytics and antipsychotics. In elderly persons with dementia, usage of antipsychotics is less appropriate because of the risk of side effects such as parkinsonism, rapid cognitive decline, cerebrovascular events and finally mortality. Furthermore, elderly persons with dementia with Lewy bodies (DLB) are often hypersensitive to antipsychotics with numerous serious adverse events such as somnolence, sedation, extra-pyramidal symptoms, delirium and increased mortality. The aim of this study was to investigate the usage of psychotropics with a focus on antipsychotics and anti-dementia medication (according to the Anatomical Therapeutic Chemical Classification System) in elderly persons with clinical signs of DLB living in dementia nursing homes (NHs) in Sweden.MethodsBetween 2012 and 2013, we applied a specially designed questionnaire that covered the clinical DLB features according to the consensus criteria of DLB. We also collected computerized medical lists from the Swedish National Medication Dispensing System from the same period. All dementia NHs (n = 40) in Malmö, the third largest city in Sweden, were covered. Of 650 eligible residents, 610 (94%) were included with 576 medical lists. The mean age was 86 years and 76% were women.ResultsTreatment with antipsychotics was seen in 22% of residents, hypnotics/sedatives in 41%, antidepressants in 50% and anxiolytics in 58%. We also found an increasing usage of antipsychotics from 25% to 43% in residents with the increasing number of DLB features. Anti-dementia medications were found in 45% of the elderly with a dementia diagnosis. However, residents with two or more DLB features had less anti-dementia medication (37%) than the rest of the dementia-diagnosed NH residents (62–69%).ConclusionsResidents with 2–4 DLB clinical features in Swedish NHs receive an unfavourable medical treatment with high antipsychotic usage and insufficient anti-dementia medication. These findings show the importance of identifying elderly persons with DLB features more effectively and improving the collaboration with nursing care to provide better medical prescription.

[1]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[2]  E. Mori.  [Dementia with Lewy bodies]. , 2000, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[3]  B. Winblad,et al.  Psychotropic drug use in elderly people with and without dementia , 2001, International journal of geriatric psychiatry.

[4]  J. Cummings,et al.  Benefit-Risk Considerations in the Treatment of Dementia with Lewy Bodies , 2002, Drug safety.

[5]  J. Heidebrink.  Is Dementia with Lewy Bodies the Second Most Common Cause of Dementia? , 2002, Journal of geriatric psychiatry and neurology.

[6]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[7]  C. Brayne,et al.  A systematic review of prevalence and incidence studies of dementia with Lewy bodies. , 2005, Age and ageing.

[8]  J. Avorn,et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.

[9]  J. Rabey,et al.  The effect of quetiapine in psychotic Parkinsonian patients with and without dementia , 2006, Journal of Neurology.

[10]  C. Ballard,et al.  Neuroleptic drugs in dementia: benefits and harm , 2006, Nature Reviews Neuroscience.

[11]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[12]  Philip S. Insel,et al.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[13]  S. Schneeweiss,et al.  Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients , 2007, Canadian Medical Association Journal.

[14]  M. Valenstein,et al.  Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. , 2007, The American journal of psychiatry.

[15]  Kelvin Lam,et al.  Antipsychotic Drug Use and Mortality in Older Adults with Dementia , 2007, Annals of Internal Medicine.

[16]  J. Fastbom,et al.  Evaluation of the quality of drug therapy among elderly patients in nursing homes , 2007, Scandinavian journal of primary health care.

[17]  E. Londos,et al.  Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease. , 2007, Alzheimer disease and associated disorders.

[18]  Quetiapine for agitation or psychosis in patients with dementia and parkinsonism , 2007, Neurology.

[19]  R. Aparasu,et al.  Antipsychotic drug use among elderly nursing home residents in the United States. , 2008, The American journal of geriatric pharmacotherapy.

[20]  K. Engedal,et al.  The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes--a 12-month follow-up study. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[21]  S. Kanba,et al.  Clinicopathological Outline of Dementia with Lewy Bodies Applying the Revised Criteria: The Hisayama Study , 2008, Brain pathology.

[22]  Dag Aarsland,et al.  Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria , 2008, Dementia and Geriatric Cognitive Disorders.

[23]  C. Pedone,et al.  Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) , 2008, Current neuropharmacology.

[24]  Stefan Günther,et al.  SuperPred: drug classification and target prediction , 2008, Nucleic Acids Res..

[25]  B. Bergman,et al.  Läkemedelsbehandling och bemötande vid beteendemässiga och psykiska symtom vid demenssjukdom – BPSD , 2008 .

[26]  E. Londos,et al.  Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial , 2009, The Lancet Neurology.

[27]  G. Deuschl,et al.  Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. , 2010, Deutsches Arzteblatt international.

[28]  L. Schneider,et al.  Trends in antipsychotic use in dementia 1999-2007. , 2011, Archives of general psychiatry.

[29]  Wendy J Mack,et al.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. , 2011, The American journal of psychiatry.

[30]  J. Snowdon,et al.  Patterns of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries , 2011, International Psychogeriatrics.

[31]  C. Wattmo,et al.  Predictors of long-term cognitive outcome in Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[32]  B. Guthrie,et al.  Differential Impact of Two Risk Communications on Antipsychotic Prescribing to People with Dementia in Scotland: Segmented Regression Time Series Analysis 2001–2011 , 2013, PloS one.

[33]  John Bond,et al.  The worldwide economic impact of dementia 2010 , 2013, Alzheimer's & Dementia.

[34]  D. Aarsland,et al.  Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. , 2014, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[35]  D. Aarsland,et al.  Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia , 2014, International journal of geriatric psychiatry.

[36]  N. Herrmann,et al.  Trends in Psychotropic Dispensing Among Older Adults with Dementia Living in Long-Term Care Facilities: 2004-2013. , 2015, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[37]  Robert Barber,et al.  Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses , 2015, The Lancet Neurology.

[38]  Alan J. Thomas,et al.  Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. , 2015, The American journal of psychiatry.

[39]  Iris Zahirovic,et al.  Prevalence of Dementia With Lewy Body Symptoms: A Cross-Sectional Study in 40 Swedish Nursing Homes. , 2016, Journal of the American Medical Directors Association.

[40]  S. Hemrungrojn,et al.  Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies , 2016, CNS neuroscience & therapeutics.

[41]  G. Waldemar,et al.  Geographical Variation in Antipsychotic Drug Use in Elderly Patients with Dementia: A Nationwide Study. , 2016, Journal of Alzheimer's disease : JAD.

[42]  S. Galetta,et al.  Editors' note: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.